RESTYLANE® EYELIGHT™

RESTYLANE® EYELIGHT™ is an FDA-approved hyaluronic acid-based dermal filler specifically designed for the treatment of infraorbital hollowing (tear troughs) in adults aged 21 and older. It features 20 mg/mL of cross-linked HA suspended in phosphate-buffered saline and includes 0.3% lidocaine for improved patient comfort. The product uses NASHA™ technology to achieve a gel with high integration and optimal lift capacity, making it ideal for the delicate periorbital region. Clinical studies have shown that RESTYLANE® EYELIGHT™ provides visible improvements lasting up to 12 months, with a median injection volume of 1.2 mL and high satisfaction rates among patients. Its safety profile is supported by extensive clinical trials with low rates of serious adverse events.

• Purpose: Correction of infraorbital hollowing
• Formulation: Cross-linked hyaluronic acid + lidocaine
• Duration of effect: Up to 12 months
• Technology: NASHA™ gel for structural support

RESTYLANE® EYELIGHT™ is administered into the supraperiosteal plane of the infraorbital area using a 29G needle or 25G–27G cannula. Physicians are advised not to exceed 1 mL per side per treatment session.

• Injection plane: Supraperiosteal (beneath the skin but above the bone)
• Needle/cannula size: 29G × ½” needle or 25G–27G × 1.5″ cannula
• Injection techniques: Linear threading, serial puncture, fanning, micro-bolus
• Recommended volume per side: Up to 1 mL
• Total typical volume (both sides): Mean 2.6 mL across treatments
• Touch-up/repeat sessions: At 1 month or 12 months as needed

RESTYLANE® EYELIGHT™ is specifically indicated for the treatment of infraorbital hollows in patients over the age of 21. It is not approved for use in vascular-rich areas or other off-label facial zones.

Indications:

• Infraorbital hollow correction (tear troughs)

Contraindications:

• Severe allergies or history of anaphylaxis
• Hypersensitivity to lidocaine or amide anesthetics
• Allergy to gram-positive bacterial proteins
• Active skin infection or inflammation in treatment area
• Bleeding disorders or anticoagulant therapy
• Pregnancy or breastfeeding

Side Effects:

• Common IREs: Swelling (85%), tenderness (89%), bruising (63%), redness (61%)
• Onset: Typically within 1–2 days
• Duration: Over 63.7% of events resolve in ≤7 days
• Rare but serious events: Vascular occlusion, vision changes, infection, necrosis

RESTYLANE® EYELIGHT™ is a clear, sterile, non-pyrogenic gel composed of cross-linked hyaluronic acid with lidocaine in a physiologic buffer.

• Hyaluronic Acid (HA): 20 mg/mL
• Lidocaine Hydrochloride: 0.3%
• Crosslinking agent: BDDE (1,4-butanediol diglycidyl ether)
• Buffer: Phosphate-buffered saline, pH ~7

Each unit of RESTYLANE® EYELIGHT™ is supplied in a single-use, prefilled syringe with sterile accessories. Traceability labels and instructions are included.

• 1 prefilled glass syringe with 1 mL of gel
• 1 sterile 29G × ½” needle
• Traceability patient record label
• Instructions for use (IFU)
• Sterile packaging with tamper-evident seal

Yes, but most side effects are mild to moderate and transient. The product has a well-documented safety profile with low rates of complications.

Common Side Effects (Injection-Related Events):

• Pain or burning (59.8%)
• Tenderness (89.7%)
• Swelling (85.0%)
• Bruising (63.1%)
• Redness, lumps, or itching

Less Common/Delayed Events:

• Injection site mass, hyperpigmentation, nodule formation
• Visual disturbances, dry eye, light sensitivity
• Post-inflammatory reactions after viral or dental procedures

Rare Serious Events:

• Infection or abscess formation
• Vascular occlusion, necrosis
• Granuloma, hypersensitivity, or neurologic symptoms

Proper storage is essential for maintaining product sterility, structure, and safety.

• Storage temperature: Up to 25°C (77°F)
• Do not freeze
• Protect from light
• Shelf life: Use before the expiration date on the package
• Do not resterilize or reuse
• Do not use if package is damaged or opened